Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 2/20 | 0.61 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.56 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.56 |
| ▸ | PLA2G4B | P0C869 | 2/20 | 0.55 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.55 |
| ▸ | LMNA | P02545 | 1/20 | 0.54 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.54 |
| ▸ | HPGD | P15428 | 1/20 | 0.52 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.52 |
| ▸ | POLB | P06746 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
| ▸ | PKM | P14618 | 1/20 | 0.51 |
| ▸ | RXRA | P19793 | 1/20 | 0.50 |
| ▸ | RXRB | P28702 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21197867 | 0.86 | GAA (0.68) | GAASMN1; SMN2ALDH1A1KDM4ELMNA | |
| SCHEMBL10765557 | 0.85 | SMN1; SMN2 (0.63) | SMN1; SMN2ALDH1A1KDM4EMAPK1LMNA | |
| SCHEMBL25758742 | 0.83 | ALDH1A1 (0.62) | GAASMN1; SMN2ALDH1A1KDM4ELMNA | |
| SCHEMBL8435551 | 0.82 | SRD5A2 (0.70) | GAASMN1; SMN2ALDH1A1SRD5A2KDM4E | |
| SCHEMBL8248742 | 0.82 | SMN1; SMN2 (0.64) | GAASMN1; SMN2ALDH1A1KDM4ELMNA | |
| SCHEMBL8241785 | 0.82 | RAB9A (0.66) | GAASMN1; SMN2ALDH1A1KDM4ELMNA | |
| SCHEMBL21217871 | 0.82 | HSD17B10 (0.56) | SMN1; SMN2ALDH1A1PLA2G4BLMNAL3MBTL1 | |
| SCHEMBL22192220 | 0.82 | ALDH1A1 (0.59) | GAASMN1; SMN2ALDH1A1KDM4EMAPK1 | |
| SCHEMBL6539261 | 0.81 | PLA2G4B (0.60) | ALDH1A1SRD5A2PLA2G4BMAPK1MAPT | |
| SCHEMBL6539782 | 0.81 | SMN1; SMN2 (0.71) | SMN1; SMN2ALDH1A1SRD5A2PLA2G4BMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230021916-A1 | MODULATORS OF RHO-ASSOCIATED PROTEIN KINASE | REDX PHARMA LIMITED (GB) | 2023-01-26 | — | — | US | disclosed |
| EP-4026834-A1 | HETEROCYCLYLAMINO-SUBSTITUTED TRIAZOLES AS MODULATORS OF RHO-ASSOCIATED PROTEIN KINASE | Redx Pharma Plc (GB) | 2022-07-13 | — | — | EP | disclosed |
| EP-3743420-B1 | HETEROCYCLYLAMINO-SUBSTITUTED TRIAZOLES AS MODULATORS OF RHO-ASSOCIATED PROTEIN KINASE | REDX PHARMA PLC (GB) | 2021-12-15 | — | — | EP | disclosed |
| US-20210038606-A1 | Modulators of Rho-associated Protein Kinase | REDX PHARMA LIMITED (GB) | 2021-02-11 | — | — | US | disclosed |
| WO-2019145729-A9 | HETEROCYCLYLAMINO-SUBSTITUTED TRIAZOLES AS MODULATORS OF RHO-ASSOCIATED PROTEIN KINASE | REDX PHARMA PLC (GB) | 2020-07-30 | — | — | WO | disclosed |
| WO-2019145729-A1 | HETEROCYCLYLAMINO-SUBSTITUTED TRIAZOLES AS MODULATORS OF RHO-ASSOCIATED PROTEIN KINASE | REDX PHARMA PLC (GB) | 2019-08-01 | — | — | WO | disclosed |
| US-6812235-B2 | 2-ACYLAMINO- BETA -ALANINE DERIVATIVES AND A PHARMACEUTICALLY ACCEPTABLE SALT, USEFUL AS FIBRINOGEN RECEPTOR ANTAGONISTS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2004-11-02 | — | — | US | disclosed |
| US-20030018193-A1 | Beta-alanine derivatives and their use as receptor anatgonists | ASTELLAS PHARMA INC. (JP) | 2003-01-23 | — | — | US | disclosed |
| EP-1255748-A1 | BETA-ALANINE DERIVATIVES AND THEIR USE AS RECEPTOR ANTAGONISTS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2002-11-13 | — | — | EP | disclosed |
| WO-2001060813-A1 | BETA-ALANINE DERIVATIVES AND THEIR USE AS RECEPTOR ANTAGONISTS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2001-08-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210038606-A1 | Modulators of Rho-associated Protein Kinase | ROCK2, ROCK1, RHOA | GAA 2427/4885SMN1; SMN2 3120/4885ALDH1A1 4405/4885 |
| US-20030018193-A1 | Beta-alanine derivatives and their use as receptor anatgonists | ARRB1, ADRB1, GLRB | GAA 422/4885SMN1; SMN2 2439/4885ALDH1A1 578/4885 |
| US-20230021916-A1 | MODULATORS OF RHO-ASSOCIATED PROTEIN KINASE | ROCK2, ROCK1, RHOA | GAA 2236/4885SMN1; SMN2 3144/4885ALDH1A1 4441/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.